A phase 1 dose escalation study of lapatinib and paclitaxel in recurrent ovarian cancer

被引：0
|
作者：
Cao, Connie D.
McCorkle, Joseph R.
Yan, Donglin
Jayswal, Rani
Miller, Rachel W.
Dietrich, Charles S.
Ueland, Frederick R.
Kolesar, Jill M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-B021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B021
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer
    Vergara, Daniele
    Bellomo, Claudia
    Zhang, Xingcai
    Vergaro, Viviana
    Tinelli, Andrea
    Lorusso, Vito
    Rinaldi, Ross
    Lvov, Yuri M.
    Leporatti, Stefano
    Maffia, Michele
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 (06) : 891 - 899
  • [32] A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer
    Juarez, Tiffany M.
    Gill, Jaya M.
    Heng, Annie
    Carrillo, Jose A.
    Wagle, Naveed
    Nomura, Natsuko
    Nguyen, Minhdan
    Truong, Judy
    Dobrawa, Lucia
    Sivakumar, Walavan
    Barkhoudarian, Garni
    Kelly, Daniel F.
    Kesari, Santosh
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [33] Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Beldner, Matthew A.
    Sherman, Carol A.
    Green, Mark R.
    Garrett-Mayer, Elizabeth
    Chaudhary, Uzair
    Meyer, Mario L.
    Kraft, Andrew S.
    Montero, Alberto J.
    BMC CANCER, 2007, 7 (1)
  • [34] Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Matthew A Beldner
    Carol A Sherman
    Mark R Green
    Elizabeth Garrett-Mayer
    Uzair Chaudhary
    Mario L Meyer
    Andrew S Kraft
    Alberto J Montero
    BMC Cancer, 7
  • [35] A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
    Myint, Zin W. W.
    St Clair, William H. H.
    Strup, Stephen E. E.
    Yan, Donglin
    Li, Ning
    Allison, Derek B. B.
    McLouth, Laurie E. E.
    Ellis, Carleton S. S.
    Wang, Peng
    James, Andrew C. C.
    Hensley, Patrick J. J.
    Otto, Danielle E. E.
    Arnold, Susanne M. M.
    DiPaola, Robert S. S.
    Kolesar, Jill M. M.
    CANCERS, 2023, 15 (09)
  • [36] A DOSE ESCALATION STUDY OF CARBOPLATIN AND IFOSFAMIDE IN ADVANCED OVARIAN-CANCER
    GALLAGHER, CJ
    WILTSHAW, E
    COLEMAN, RE
    HARPER, PG
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (01) : 54 - 57
  • [37] A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cancer.
    Iwata, H
    Mizutani, M
    Kamei, K
    Toyama, T
    Ando, Y
    Ota, D
    Kawaguchi, N
    Shigemori, C
    Iwase, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 51S - 51S
  • [38] Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
    Havrilesky, LJ
    Alvarez, AA
    Sayer, RA
    Lancaster, JM
    Soper, JT
    Berchuck, A
    Clarke-Pearson, DL
    Rodriguez, GC
    Carney, ME
    GYNECOLOGIC ONCOLOGY, 2003, 88 (01) : 51 - 57
  • [39] The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer
    Cadron, Isabelle
    Leunen, Karin
    Amant, Frederic
    Van Gorp, Toon
    Neven, Patrick
    Vergote, Ignace
    GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 354 - 361
  • [40] ANALYSIS OF EXPOSURE TIMES AND DOSE-ESCALATION OF PACLITAXEL IN OVARIAN-CANCER CELL-LINES
    ADLER, LM
    HERZOG, TJ
    WILLIAMS, S
    RADER, JS
    MUTCH, DG
    CANCER, 1994, 74 (07) : 1891 - 1898
12345